NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Technology Appraisal (Committee D) meeting minutes

**Minutes:** Confirmed

**Date and time:** Wednesday 5 August 2020 – 09.30am

**Location:** Via Zoom

## Committee members present:

1. Professor Gary McVeigh [Chair] Present for all items
2. Steve O’Brien [Chair] Present for items 4 to 4.3.2
3. Dr Lindsay Smith [Vice Chair] Present for all items
4. Dr Nabeel Alsindi Present for all items
5. Carlo Berti Present for Items 1 to 3.3.2
6. Sofia Dias Present for all items
7. Steve Edwards Present for items 4 to 4.3.2
8. Gillian Ells Present for all items
9. David Foreman Present for Items 1 to 3.3.2
10. Dr Rebecca Harmston Present for all items
11. Dr Robert Hodgson Present for all items
12. Dr Bernard Khoo Present for all items
13. Dr Soo Fon Lim Present for all items
14. Amanda Matse-Orere Present for Items 1 to 3.3.2
15. Professor David Meads Present for all items
16. Giles Monnickendam Present for all items
17. Malcolm Oswald Present for all items
18. Anna Pracz Present for all items
19. Baljit Singh Present for all items

## NICE staff present:

Linda Landalls, Associate Director Present for all items

Gavin Kenny, Project Manager Present for all items

Kate Moore, Project Manager Present for items 4 to 4.3.2

Christian Griffiths, Technical Advisor Present for items 1 to 3.3.2

Nicola Hay, Technical Advisor Present for items 4 to 4.3.2

Adam Brooke, Technical Analyst Present for items 1 to 3.3.2

Thomas Paling, Technical Analyst Present for item 4 to 4.3.2

Laura Marsden, Coordinator [COT] Present for 1 to 3.3.2

Sandra Robinson, Coordinator [MIP] Present for 1 to 3.2 & 4 to 4.2

Gemma Smith, Coordinator [COT] Present for all items

Mandy Tonkinson, Coordinator [PIP] Present for items 1 to 3.2

Ismahan Abdullah, Administrator [TA] Present for items 1 to 3.3.2

Celia Mayers, Administrator [TA] Present for items 4 to 4.3.2

## External group representatives present:

Robert Wolff, Deputy Director, Kleijnen Systematic Reviews Ltd Present for items 1 to 3.2

Nigel Armstrong, Health Economist, Kleijnen Systematic Reviews Ltd Present for items 1 to 3.2

## Professional experts present:

Professor Hamish McAllister-Williams, Clincal expert, Consultant Psychiatrist, Newcastle University Present for items 1 to 3.2

Peter Pratt, Head of medicines strategy mental health, NHS England Present for items 1 to 3.2

Esther Monaghan Patient expert Present for items 1 to 3.2

Peter Clark, CDF Lead, NHS England Present for items 4 to 4.3.2

## Observers present:

Matthew Brown, Digital Media Manager, NICE Present for items 1 to 3.3.2

Emilene Coventry, Senior Medical Editor, NICE Present for items 4 to 4.3.2

Henry Edwards, Technical Analyst, NICE Present for all items

Olivia Havercroft, Senior Medical Editor, NICE Present for items 1 to 3.3.2

Emma Jones, Senior Medical Editor, NICE Present for items 1 to 3.3.2

Laura Marsden, Coordinator, NICE Present for items 1 to 3.3.2

Maroulla Whiteley, Business Analyst [RIA], NICE Present for items 4 to 4.3.2

Willem Wiltox, Kleijnen Systematic Reviews, Present for items 1 to 3.2

## Introduction to the meeting

The chair welcomed members of the committee and other attendees present to the meeting.

The chair noted apologies from; Dr Andrew Hitchings, Dr Guy Makin, James Avery, Libby Mills, Professor Paula Ghaneh, Professor Rachel Elliott.

## News and announcements

None

## Appraisal of Esketamine for treatment-resistant depression [ID1414]

### Part 1 – Open session

The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Janssen.

The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Giles Monnikendam declared a non-financial personal interest as his employer [Vitaccess] is developing an observational study for Teva which is a possible comparator company in an unrelated indication [migraine]. It was agreed that this declaration would not prevent Giles from attending any discussions on this topic
* Dr Matt Bradley declared a financial interest as his employer GSK is identified as a comparator company. It was agreed that this declaration would prevent Matt from attending any discussions on this topic.
* Hamish McAllister declared financial & non-financial interests as he is recruiting participants to two commercial studies funded by COMPASS pathways and LivaNova, also over the last 3 years he has received fees for consultancy or giving talks at educational meetings from a number of pharmaceutical and neuromodulatory companies including Lundbeck, Sunovian, LivaNova, Magstim, Syntropharma, Pfizer, P1vital and Janssen. It was agreed that his declarations would not prevent Hamish from providing expert advice to the committee on this item.

No further conflicts of interest were declared for this item.

The committee discussed confidential information submitted for this item

### Part 2 - Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting]

The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.

The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## Appraisal of Osimertinib for untreated EGFR mutation-positive non-small cell lung cancer [rapid review TA621] [ID3786]

### Part 1 – Open session

The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from AstraZeneca.

The chair asked all committee members, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Amanda Matse-Orere declared a financial interest as she works for comparator company, Roche. It was agreed that her declaration would prevent Amanda from attending any discussions on this topic.
* Matt Bradley declared a financial interest as he holds shares in AstraZeneca. It was agreed that his declaration would prevent Matt from attending any discussions on this topic.

No further conflicts of interest were declared for this item.

The committee discussed confidential information submitted for this item.

### Part 2 - Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting].

The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus..

The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Date of the next meeting

The next meeting of the Technology Appraisal (Committee D) will be held on Wednesday 2 September 2020 and will start promptly at 09.30am.